Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13584664 | 0.99 | CA12 (0.45) | CA12CA1CA9EPHX1MAPT | |
| SCHEMBL13583763 | 0.90 | EPHX1 (0.52) | CA12CA1CA9EPHX1EPHX2 | |
| SCHEMBL13584269 | 0.89 | MEN1 (0.45) | EPHX1MAPTMEN1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL13584449 | 0.89 | EPHX1 (0.51) | CA12CA1CA9EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL13584472 | 0.88 | MEN1 (0.44) | EPHX1MAPTMEN1LMNAKMT2A | |
| SCHEMBL20315926 | 0.85 | HSD17B10 (0.43) | CA12CA1CA9MAPTMEN1 | |
| SCHEMBL14868691 | 0.81 | GAA (0.51) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL13584733 | 0.79 | MEN1 (0.60) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL29518687 | 0.79 | MEN1 (0.60) | MAPTMEN1LMNAKMT2AHTT | |
| SCHEMBL13585147 | 0.78 | GAA (0.44) | CA12CA1CA9MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | claimed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | claimed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | claimed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | claimed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | claimed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10272055-B2 | Therapeutic compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | PRKAG1, PRKAG3, PRKAG2 | CA12 3473/4885CA1 3104/4885CA9 1476/4885 |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG2, PRKAG3 | CA12 3578/4885CA1 3181/4885CA9 1606/4885 |
| US-20150342909-A1 | THERAPEUTIC COMPOUNDS AND METHODS | G6PD, BRCA1, BPGM | CA12 846/4885CA1 3067/4885CA9 403/4885 |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG3, PRKAG2 | CA12 3487/4885CA1 3086/4885CA9 1520/4885 |
| US-10272055-B2 | Therapeutic compounds and methods | G6PD, BRCA1, BPGM | CA12 846/4885CA1 3067/4885CA9 403/4885 |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | PRKAG1, PRKAG3, PRKAG2 | CA12 3473/4885CA1 3104/4885CA9 1476/4885 |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | EPHX1, EPHX2, CYP4X1 | CA12 1712/4885CA1 2369/4885CA9 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.